Improved survival in chronic lymphocytic leukemia
Progression-free survival was improved in patients with chronic lymphocytic leukemia (CLL) who receive the combination of rituximab, fludarabine, and cyclophosphamide. Results of the phase III REACH study demonstrated a median improvement in progression-free survival of 10 months when compared with fludarabine and cyclophosphamide alone. In addition, complete response rates [...]